Table 4.

Effect of CHIR-258 or dexamethasone or both on KMS11 viability

Treatment (concentration)
Viability as % of control ± SD
DMSO   100%  
Dexamethasone (0.5 μM)   87% ± 4.74  
CHIR-258 (100 nM)   49% ± 4.64  
Dexamethasone (0.5 μM) and CHIR-258 (100 nM)
 		 10% ± 6.48
 
Treatment (concentration)
Viability as % of control ± SD
DMSO   100%  
Dexamethasone (0.5 μM)   87% ± 4.74  
CHIR-258 (100 nM)   49% ± 4.64  
Dexamethasone (0.5 μM) and CHIR-258 (100 nM)
 		 10% ± 6.48
 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal